Related Experiment Video
Updated: Feb 2, 2026
Mouse Model of Metabolic Dysfunction-Associated Steatotic Liver Disease with Fibrosis
Published on: July 18, 2025
Multicenter Prospective Cohort Study on Clinical Outcomes and Fibrosis Patterns in Biopsy-Proven Steatotic Liver
Gi-Ae Kim1, Heejoon Jang2, Moon Young Kim3
1Division of Gastroenterology and Hepatology, Department of Internal Medicine, College of Medicine, Kyung Hee University Hospital, Kyung Hee University, Seoul, South Korea.
Background & Aims:
Clinical outcomes and histologic characteristics of biopsy-proven steatotic liver disease (SLD) subtypes remain understudied. We investigated clinical outcomes and fibrosis patterns in metabolic dysfunction-associated steatotic liver disease (MASLD), metabolic dysfunction and alcohol-related liver disease (MetALD), and alcohol-associated liver disease (ALD).
Methods:
This multicenter prospective cohort study enrolled 2551 individuals with biopsy-proven SLD or non-SLD controls between 2010 and 2023. Risks of all-cause mortality, liver-related events (LREs), cardiovascular disease, and extrahepatic malignancies were assessed using Fine-Gray models. Artificial intelligence (AI)-based quantitative fibrosis analysis using second harmonic generation imaging was performed on 88 liver biopsies (28 MASLD, 30 MetALD, and 30 ALD) to assess zone-specific collagen distribution patterns.
Results:
During a median follow-up of 43.8 months, 166 deaths and 162 LREs occurred. Compared with non-SLD, MetALD (adjusted subdistribution hazard ratio [ASHR], 3.05; 95% confidence interval [CI], 1.08-8.58) and ALD (ASHR, 5.80; 95% CI, 2.26-14.87) demonstrated substantially increased all-cause mortality risk. MetALD (ASHR, 6.13; 95% CI, 1.33-28.20) and ALD (ASHR, 10.96; 95% CI, 2.55-47.14) also exhibited elevated LRE risk. In the advanced fibrosis (≥F3) subgroup, ALD demonstrated higher mortality and LRE risks than MASLD. AI-based analysis revealed that MetALD and ALD exhibited significantly higher collagen density in periportal and zone 2 regions compared with MASLD, despite comparable conventional fibrosis stages.
Conclusions:
MetALD and ALD are independently associated with substantially increased all-cause mortality and LRE risks compared with non-SLD. Distinct zone-specific collagen patterns identified by AI analysis suggest unique fibrotic progression pathways in MetALD and ALD, supporting the need for tailored risk stratification and targeted management strategies.
More Related Videos
Related Concept Videos
01:22Rheumatic Heart Disease II: Clinical Manifestations and Diagnostic Studies
01:26Diseases of the Liver and Gallbladder
Cirrhosis is characterized by the scarring of hepatic lobules in the liver, which are replaced by fibrous tissue, affecting the liver's normal functioning. NAFLD, on the other hand, is caused by an excessive build-up of fat in the liver, not...
01:28Peptic Ulcer Disease III: Clinical Manifestations and Diagnostic Studies
Few clinical manifestations differentiate gastric ulcers from duodenal ulcers. Distinctions in the location, timing, and pain relief are crucial for healthcare providers in differentiating between gastric and duodenal ulcers during clinical assessments.
01:24Chronic Kidney Disease II: Clinical Manifestations
01:30Coronary Artery Disease III: Clinical Manifestations
01:29Gastroesophageal Reflux Disease II: Clinical Features and Management
Clinical Manifestations
GERD presents itself in a multitude of ways, with symptoms varying from person to person. The hallmark symptoms are...